Literature DB >> 15851483

Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage.

Dmitri Wiederschain1, Hidehiko Kawai, Ali Shilatifard, Zhi-Min Yuan.   

Abstract

Chromosomal translocations involving the mixed lineage leukemia (MLL) gene are often observed in acute leukemias of both myeloid and lymphocytic origin. Expression of MLL fusion proteins is known to induce malignant transformation of normal blood progenitors; however, molecular mechanisms of this process are still poorly understood. In this study we investigated the effect of several frequently detected MLL fusion proteins on p53 transcriptional activity. Our data show that MLL-AF9, MLL-AF10, MLL-ENL, and MLL-ELL substantially down-regulate p53-mediated induction of p21, MDM2, and Bax in response to DNA damage. Furthermore, we identify the reduction in p53 acetylation by p300 as a major mechanism of the inhibitory effect of MLL leukemic fusions. Our data suggest that abrogation of p53 functional activity can be a common feature of MLL fusion-mediated leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15851483     DOI: 10.1074/jbc.M412237200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.

Authors:  Benjamin Mizukawa; Junping Wei; Mahesh Shrestha; Mark Wunderlich; Fu-Sheng Chou; Andrea Griesinger; Chad E Harris; Ashish R Kumar; Yi Zheng; David A Williams; James C Mulloy
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

Review 2.  Causes of oncogenic chromosomal translocation.

Authors:  Peter D Aplan
Journal:  Trends Genet       Date:  2005-10-28       Impact factor: 11.639

3.  Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.

Authors:  Cecily A Bennett; Amanda C Winters; Nisha N Barretto; Charles S Hemenway
Journal:  Leuk Res       Date:  2009-02-20       Impact factor: 3.156

4.  Characterization of DNA damage-dependent cell cycle checkpoints in a menin-deficient model.

Authors:  Molly C Kottemann; Allen E Bale
Journal:  DNA Repair (Amst)       Date:  2009-07-15

5.  Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation.

Authors:  Jiangang Zhou; Xi Feng; Bin Ban; Jingxia Liu; Zhou Wang; Wuhan Xiao
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

6.  Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.

Authors:  Alex H Beesley; Janelle L Rampellini; Misty-Lee Palmer; Jasmin Y S Heng; Amy L Samuels; Martin J Firth; Jette Ford; Ursula R Kees
Journal:  Mol Cancer       Date:  2010-10-28       Impact factor: 27.401

7.  Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis.

Authors:  Dmitri Wiederschain; Lin Chen; Brett Johnson; Kimberly Bettano; Dowdy Jackson; John Taraszka; Y Karen Wang; Michael D Jones; Michael Morrissey; James Deeds; Rebecca Mosher; Paul Fordjour; Christoph Lengauer; John D Benson
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

Review 8.  The molecular biology of mixed lineage leukemia.

Authors:  Robert K Slany
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

9.  Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Authors:  Nadine Hein; Donald P Cameron; Katherine M Hannan; Nhu-Y N Nguyen; Chun Yew Fong; Jirawas Sornkom; Meaghan Wall; Megan Pavy; Carleen Cullinane; Jeannine Diesch; Jennifer R Devlin; Amee J George; Elaine Sanij; Jaclyn Quin; Gretchen Poortinga; Inge Verbrugge; Adele Baker; Denis Drygin; Simon J Harrison; James D Rozario; Jason A Powell; Stuart M Pitson; Johannes Zuber; Ricky W Johnstone; Mark A Dawson; Mark A Guthridge; Andrew Wei; Grant A McArthur; Richard B Pearson; Ross D Hannan
Journal:  Blood       Date:  2017-03-10       Impact factor: 22.113

10.  Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Authors:  Mona Meyer; Daniela Rübsamen; Robert Slany; Thomas Illmer; Kathleen Stabla; Petra Roth; Thorsten Stiewe; Martin Eilers; Andreas Neubauer
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.